Stock NKGN NKGEN BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages NKGen Biotech, Inc. Nyse

Equities

NKGN

US65488A1016

Delayed Nyse
Other stock markets
 18:24:36 17/05/2024 BST 		5-day change 1st Jan Change
1.1 USD -2.62% Intraday chart for NKGen Biotech, Inc. -10.40% -86.74%
04-29 Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease CI
04-29 NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LP CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease
NKGen Biotech, Inc. Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit
NKGen Biotech, Inc. Presents Additional Phase 1 Clinical Trial Data in Alzheimer?s Disease At the Tau2024 Global Conference
NKGen Biotech, Inc. Announces Resignation of Sangwoo Park as Chairperson of the Board
NKGen Biotech, Inc. Announces Resignation of Alana Mcnulty as Director and as A Member of Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee
NKGen Biotech Doses First Patient in Clinical Trial for Alzheimer's Disease Therapy
Sector Update: Health Care Stocks Edge Higher Premarket Friday
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's Disease
NKGen Biotech Gets Canadian Regulator's Clearance to Study NK Cell Therapy for Alzheimer's
NKGen Biotech Inc. Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease
Wall Street Set to Open Higher Friday; Core Inflation Rises 0.3% Matching Forecast
US Futures Mixed as Investors Look Toward Personal Income, Consumer Sentiment Reports
Top Premarket Gainers
Nkgen Biotech Presented Phase I Clinical Trial Data At the 16Th Annual Clinical Trials on Alzheimer's Disease Conference
Sector Update: Health Care Stocks Advance in Late Afternoon Trading
NKGen Biotech Gets FDA Clearance to Start Alzheimer's Disease Trial; Shares Jump
NKGen Biotech, Inc. Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer's Disease
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NKGN Stock
  4. NKGN Stock
  5. News NKGen Biotech, Inc.
  6. Other languages